Screener
Celldex Therapeutics CLDX Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Celldex Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
FAQ
- What is Celldex Therapeutics's return on equity?
- Celldex Therapeutics (CLDX) reported return on equity of -43.9% in Q2 2026.
- How has Celldex Therapeutics's return on equity changed year-over-year?
- Celldex Therapeutics's return on equity decreased by 61.5% year-over-year, from -27.2% to -43.9%.
- What is the long-term trend for Celldex Therapeutics's return on equity?
- Over 5 years (2020 to 2025), Celldex Therapeutics's return on equity has grown at a 0.6% compound annual growth rate (CAGR), from -39.4% to -40.6%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about Celldex Therapeutics's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude